Wassim Aldairy

Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer

Jason T Chittenden, Meng Chen, M. Borin, 2015, Cancer Chemotherapy and Pharmacology.

Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program

V. Paton, M. Merchant, P. Luhn, 2015, PloS one.